Find trials
Search tips

Liver Kinase B1 and Interstitial Fibrosis and Tubular Atrophy and Kidney Transplant Recipients

Overview

About this study

The purpose of this study is to investigate expression of LKB1 in exosomes in urine and plasma of kidney transplant recipients and define its impact on development of interstitial fibrosis and tubular atrophy (IFTA).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subjects 18 – 85 years of age.
  • Subjects who understand that participation is voluntary.
  • Subjects who are able to complete the informed consent process.
  • Patients with kidney transplantation done in Mayo clinic Arizona from June, 1, 2013 to January 1, 2025.

Exclusion Criteria: 

  • Subjects who are younger than 18 years of age.
  • Pregnant women.
  • simultaneous dual organ transplant.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/11/23. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Sumi Nair, M.B.B.S., M.D.

Open for enrollment

Contact information:

Gabrielle Montefiore

(480) 574-1288

Montefiore.Gabrielle@mayo.edu

More information

Publications

Publications are currently not available

More about research at Mayo Clinic

.
CLS-20557404

Mayo Clinic Footer